This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bergese, S. D. Articles by Orosz, C. G. Search for Related Content PubMed PubMed Citation Articles by Bergese, S. D. Articles by Orosz, C. G.

American Journal of Pathology, Vol 147, 166-175, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection

SD Bergese, EH Huang, RP Pelletier, MB Widmer, RM Ferguson and CG Orosz
Department of Surgery, Ohio State University College of Medicine, Columbus, OH 43210, USA.

This report provides evidence to support the hypothesis that tumor necrosis factor-alpha (TNF-alpha) and IL-4 promote the expression of new endothelial surface molecules in rejecting murine heterotopic cardiac allografts. The microvascular endothelia of these cardiac allografts all develop strong reactivity with the monoclonal antibodies (mAbs) YN1.1/74 (anti-ICAM-1), M/K-2 (anti-VCAM-1) and MECA-32 (undefined molecule) within 3 to 5 days of graft implantation. Daily treatment of the allograft recipients with pentoxifylline (PTX), soluble TNF receptor (TNFR:Fc), anti-interleukin-4 (IL-4) mAb (11B11), or soluble IL-4 receptor, each abrogate the expression of endothelial VCAM-1 and reduce the endothelial reactivity with the mAbs YN1.1/74 and MECA-32 to levels found in cardiac isografts. This is accompanied by a reduction, but not an elimination, of interstitial leukocytic infiltration. Despite this, cardiac allograft recipients treated with PTX or the mAb 11B11 rejected allografts at the same rate as untreated allograft recipients, ie, within 10 to 12 days after graft implantation. These rejected grafts contained mRNAs for TNF-alpha and IL-4, as well as for all other cytokines that have been associated with rejecting allografts. This suggests that endothelial VCAM-1 expression, which is characteristic of rejection, is not an essential element of the rejection process. Interestingly, the grafts from the PTX-treated recipients continued to display rare, isolated VCAM-1 positive cells in the interstitium, which may be dendritic cells. In general, these studies demonstrate a role for IL-4 and TNF-alpha in the alterations of vascular endothelial phenotype observed in rejecting cardiac allografts. They also demonstrate that endothelial VCAM-1 expression is not essential for the allograft rejection process, and that the role of VCAM-1 in this process may be more subtle than was initially suspected.

This article has been cited by other articles:

				N. Shimoda, N. Fukazawa, K. Nonomura, and R. L. Fairchild Cathepsin G Is Required for Sustained Inflammation and Tissue Injury after Reperfusion of Ischemic Kidneys Am. J. Pathol., March 1, 2007; 170(3): 930 - 940. [Abstract] [Full Text] [PDF]

				K. Inagaki, E. Churchill, and D. Mochly-Rosen Epsilon protein kinase C as a potential therapeutic target for the ischemic heart Cardiovasc Res, May 1, 2006; 70(2): 222 - 230. [Abstract] [Full Text] [PDF]

				T. El-Sawy, J. A. Belperio, R. M. Strieter, D. G. Remick, and R. L. Fairchild Inhibition of Polymorphonuclear Leukocyte-Mediated Graft Damage Synergizes With Short-Term Costimulatory Blockade to Prevent Cardiac Allograft Rejection Circulation, July 19, 2005; 112(3): 320 - 331. [Abstract] [Full Text] [PDF]

				E. W. Raines and N. Ferri Thematic Review Series: The Immune System and Atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease J. Lipid Res., June 1, 2005; 46(6): 1081 - 1092. [Abstract] [Full Text] [PDF]

				M. Tanaka, F. Gunawan, R. D. Terry, K. Inagaki, A. D. Caffarelli, G. Hoyt, P. S. Tsao, D. Mochly-Rosen, and R. C. Robbins Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1160 - 1167. [Abstract] [Full Text] [PDF]

				M. Tanaka, R. D. Terry, G. K. Mokhtari, K. Inagaki, T. Koyanagi, T. Kofidis, D. Mochly-Rosen, and R. C. Robbins Suppression of Graft Coronary Artery Disease by a Brief Treatment With a Selective {epsilon}PKC Activator and a {delta}PKC Inhibitor in Murine Cardiac Allografts Circulation, September 14, 2004; 110(11_suppl_1): II-194 - II-199. [Abstract] [Full Text] [PDF]

				T. El-Sawy, M. Miura, and R. Fairchild Early T Cell Response to Allografts Occuring Prior to Alloantigen Priming Up-Regulates Innate-Mediated Inflammation and Graft Necrosis Am. J. Pathol., July 1, 2004; 165(1): 147 - 157. [Abstract] [Full Text] [PDF]

				M. Miura, K. Morita, H. Kobayashi, T. A. Hamilton, M. D. Burdick, R. M. Strieter, and R. L. Fairchild Monokine Induced by IFN-{gamma} Is a Dominant Factor Directing T Cells into Murine Cardiac Allografts During Acute Rejection J. Immunol., September 15, 2001; 167(6): 3494 - 3504. [Abstract] [Full Text] [PDF]

				K. Morita, M. Miura, D. R. Paolone, T. M. Engeman, A. Kapoor, D. G. Remick, and R. L. Fairchild Early Chemokine Cascades in Murine Cardiac Grafts Regulate T Cell Recruitment and Progression of Acute Allograft Rejection J. Immunol., September 1, 2001; 167(5): 2979 - 2984. [Abstract] [Full Text] [PDF]

				A C S. Ventura and M Bohnke Pentoxifylline influences the autocrine function of organ cultured donor corneas and enhances endothelial cell survival Br. J. Ophthalmol., September 1, 2001; 85(9): 1110 - 1114. [Abstract] [Full Text] [PDF]

				Y. Watarai, S. Koga, D. R. Paolone, T. M. Engeman, C. Tannenbaum, T. A. Hamilton, and R. L. Fairchild Intraallograft Chemokine RNA and Protein During Rejection of MHC-Matched/Multiple Minor Histocompatibility-Disparate Skin Grafts J. Immunol., June 1, 2000; 164(11): 6027 - 6033. [Abstract] [Full Text] [PDF]

				L. C. BORISH, H. S. NELSON, M. J. LANZ, L. CLAUSSEN, J. B. WHITMORE, J. M. AGOSTI, and L. GARRISON Interleukin-4 Receptor in Moderate Atopic Asthma . A Phase I/II Randomized, Placebo-controlled Trial Am. J. Respir. Crit. Care Med., December 1, 1999; 160(6): 1816 - 1823. [Abstract] [Full Text]

				S. Koga, M. B. Auerbach, T. M. Engeman, A. C. Novick, H. Toma, and R. L. Fairchild T Cell Infiltration into Class II MHC-Disparate Allografts and Acute Rejection Is Dependent on the IFN-{gamma}-Induced Chemokine Mig J. Immunol., November 1, 1999; 163(9): 4878 - 4885. [Abstract] [Full Text] [PDF]

				O. V. Volpert, T. Fong, A. E. Koch, J. D. Peterson, C. Waltenbaugh, R. I. Tepper, and N. P. Bouck Inhibition of Angiogenesis by Interleukin 4  J. Exp. Med., September 21, 1998; 188(6): 1039 - 1046. [Abstract] [Full Text] [PDF]

				M.-J. Sanz, L. Marinova-Mutafchieva, P. Green, R. R. Lobb, M. Feldmann, and S. Nourshargh IL-4-Induced Eosinophil Accumulation in Rat Skin Is Dependent on Endogenous TNF-{alpha} and {alpha}4 Integrin/VCAM-1 Adhesion Pathways J. Immunol., June 1, 1998; 160(11): 5637 - 5645. [Abstract] [Full Text] [PDF]